PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS • Unmet needs of available AEDs • Pipeline drugs for epilepsy PART 06: MARKET SIZING • Market definition PART 07: MARKET SIZING 2017 • Market definition • Market size and forecast 2017-2022 PART 08: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 09: MARKET SEGMENTATION BY DRUG ACTIVITY SPECTRUM • Segmentation by drug activity spectrum • Comparison by drug activity spectrum • Narrow spectrum drugs – Market size and forecast 2017-2022 • Broad spectrum drugs – Market size and forecast 2017-2022 • Market opportunity by drug activity spectrum PART 10: MARKET SEGMENTATION BY ETIOLOGY • Segmentation by etiology PART 11: MARKET SEGMENTATION BY AGE OF ONSET • Segmentation by age of onset PART 12: CUSTOMER LANDSCAPE PART 13: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 14: DECISION FRAMEWORK PART 15: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 16: MARKET TRENDS • Increase in epilepsy management costs • Use of immunotherapy and immunomodulators • Use of genetics as therapeutics and diagnostic modality • Research in precision healthcare infrastructure PART 17: VENDOR LANDSCAPE • Overview • Landscape disruption PART 18: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Eisai • GlaxoSmithKline • Novartis • Pfizer PART 19: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global CNS disorders therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Need, demand, and supply analysis of AEDs Exhibit 06: Pipeline drugs under phase III development Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2017 Exhibit 09: Validation techniques employed for market sizing 2017 Exhibit 10: Global epilepsy drugs market – Market size and forecast 2017-2022 ($ bn) Exhibit 11: Global epilepsy drugs market – Year over year growth 2018-2022 (%) Exhibit 12: Five forces analysis 2017 Exhibit 13: Five forces analysis 2022 Exhibit 14: Bargaining power of buyers Exhibit 15: Bargaining power of suppliers Exhibit 16: Threat of new entrants Exhibit 17: Threat of substitutes Exhibit 18: Threat of rivalry Exhibit 19: Market condition - Five forces 2017 Exhibit 20: Global epilepsy drugs market by drug activity spectrum – Market share 2017-2022 (%) Exhibit 21: Comparison by drug activity spectrum Exhibit 22: Global epilepsy drugs market by narrow spectrum drugs – Market size and forecast 2017-2022 ($ bn) Exhibit 23: Global epilepsy drugs market by narrow spectrum drugs – Year over year growth 2018-2022 (%) Exhibit 24: Global epilepsy drugs market by broad spectrum drugs – Market size and forecast 2017-2022 ($ bn) Exhibit 25: Global epilepsy drugs market by broad spectrum drugs – Year over year growth 2018-2022 (%) Exhibit 26: Market opportunity by drug activity spectrum Exhibit 27: Customer Landscape Exhibit 28: Global epilepsy drugs market by region – Market share 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Epilepsy drugs market in Americas – Market size and forecast 2017-2022 ($ bn) Exhibit 31: Epilepsy drugs market in Americas – Year over year growth 2018-2022 (%) Exhibit 32: Top three countries in Americas Exhibit 33: Epilepsy drugs market in EMEA – Market size and forecast 2017-2022 ($ bn) Exhibit 34: Epilepsy drugs market in EMEA – Year over year growth 2018-2022 (%) Exhibit 35: Top three countries in EMEA Exhibit 36: Epilepsy drugs market in APAC – Market size and forecast 2017-2022 ($ bn) Exhibit 37: Epilepsy drugs market in APAC – Year over year growth 2018-2022 (%) Exhibit 38: Top three countries in APAC Exhibit 39: Market opportunity Exhibit 40: Examples of epilepsy drugs discontinued due to safety issues: Exhibit 41: Epilepsy management costs Exhibit 42: Price of leading branded AEDs Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Eisai overview Exhibit 49: Eisai – Business segments Exhibit 50: Eisai – Organizational developments Exhibit 51: Eisai – Geographic focus Exhibit 52: Eisai – Segment focus Exhibit 53: Eisai – Key offerings Exhibit 54: GlaxoSmithKline overview Exhibit 55: GlaxoSmithKline – Business segments Exhibit 56: GlaxoSmithKline – Organizational developments Exhibit 57: GlaxoSmithKline – Geographic focus Exhibit 58: GlaxoSmithKline – Segment focus Exhibit 59: GlaxoSmithKline – Key offerings Exhibit 60: Novartis overview Exhibit 61: Novartis – Business segments Exhibit 62: Novartis – Organizational developments Exhibit 63: Novartis – Geographic focus Exhibit 64: Novartis – Segment focus Exhibit 65: Novartis – Key offerings Exhibit 66: Pfizer overview Exhibit 67: Pfizer – Business segments Exhibit 68: Pfizer – Organizational developments Exhibit 69: Pfizer – Geographic focus Exhibit 70: Pfizer – Segment focus Exhibit 71: Pfizer – Key offerings

Eisai GlaxoSmithKline Novartis Pfizer